Showing 1191-1200 of 1395 results for "".
- Novartis Issues Summary Financial Information for the Alcon Eye Care Business Ahead of Shareholder Votehttps://modernod.com/news/novartis-issues-summary-financial-information-for-the-alcon-eye-care-business-ahead-of-shareholder-vote/2476260/Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon at the Novartis Annual General Meeting of Shareholders (AGM) on February 28, 2019. The issuance of the short form fi
- College of Optometrists in Vision Development & NORA Issue Joint Recommendation for Optometric Evaluation Following Brain Injuryhttps://modernod.com/news/college-of-optometrists-in-vision-development-nora-issue-joint-recommendation-for-optometric-evaluation-following-brain-injury/2476285/The College of Optometrists in Vision Development (COVD) and the Neuro Optometric Rehabilitation Association (NORA) issued a joint call-to-action to all healthcare professionals to consider the need for medical and/or functional optometric rehabilitation services for patients who have suffered a
- iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery (STAR-I)https://modernod.com/news/istar-medicals-miniject-maintains-exceptional-results-in-first-in-human-trial-one-year-post-surgery-star-i/2476244/iSTAR Medical announced 1-year results of the first-in-human, microinvasive glaucoma surgery (MIGS) STAR-I trial, for the MINIject device in a standalone setting. Results demonstrate that MINIject is safe and highly effective in achieving significant IOP reduction, as well as easing medication bu
- Study: Glaukos iStent inject Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burdenhttps://modernod.com/news/study-glaukos-istent-inject-implantation-with-concomitant-cataract-surgery-provides-sustained-reduction-in-iop-and-medication-burden/2479620/Glaukos announced that a single-site international study of glaucoma subjects recently published in Ophthalmology and Therapy showed that the iStent inject Trabecular Micro-Bypass System, combined with cataract surgery, achieved a 37% reduction in mean IOP to 14.3 mmHg after 3 years of f
- Permanent J Code Issued for Avedro’s Photrexa Drug Formulationshttps://modernod.com/news/permanent-j-code-issued-for-avedros-photrexa-drug-formulations/2479654/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) issued a product-specific J code, J2787, for Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5’-phosphate ophthalmic solution). These Photrexa formulations are the onl
- Johnson & Johnson Vision Announce $26.35 Million Collaboration for Prevention and Treatment of Myopiahttps://modernod.com/news/johnson-johnson-vision-announce-26-35-million-collaboration-for-prevention-and-treatment-of-myopia/2479677/The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI), and Johnson & Johnson Vision announced a $26.35 million research collaboration to tackle myopia. By 2050, half of the world’s population are projected to be myopic, with one billion expected to have high my
- Santen Announces Initiation of Phase 3 Clinical Program (SPECTRUM) Evaluating Glaucoma Treatment Omidenepag Isopropyl (DE-117)https://modernod.com/news/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension/2479772/Santen announced the initiation of the pivotal phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or o
- Topcon Announces Date for 3rd Annual ISSOCT Conferencehttps://modernod.com/news/topcon-announces-date-for-3rd-annual-issoct-conference/2479931/Topcon Medical Systems has announced that the 3rd Annual ISSOCT Conference will be held on February 10-11, 2019 at the Sanibel Harbour Marriott Resort in Fort Myers, Florida. The world’s leading ophthalmologist
- Lightmed Announces New Office Location in Caesarea, Israelhttps://modernod.com/news/lightmed-announces-new-office-location-in-caesarea-israel/2480027/Lightmed announced it has opened a new office location in Caesarea, Israel to expand its business and technological investments, and leverage Israel’s diverse and experienced medical technology talent pool. “Th
- Glaukos Announces FDA Approval for the iStent inject Trabecular Micro-Bypass Systemhttps://modernod.com/news/glaukos-announces-fda-approval-for-the-istent-inject-trabecular-micro-bypass-system/2480073/Glaukos announced it has received premarket approval from the FDA for the »iStent inject Trabecular Micro-Bypass System, which is indicated for the reduction of IOP in adult